Memantine in moderate-to-severe Alzheimer's disease.
暂无分享,去创建一个
Rachelle Doody | B. Reisberg | F. Schmitt | R. Doody | S. Ferris | A. Stöffler | Barry Reisberg | Steven Ferris | Albrecht Stöffler | Frederick Schmitt | Hans Jörg Möbius | H. Möbius
[1] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[2] R. Katzman.,et al. Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.
[3] B. Reisberg,et al. The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.
[4] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[5] F. Fonnum. Glutamate: A Neurotransmitter in Mammalian Brain , 1984, Journal of neurochemistry.
[6] B. Reisberg. Functional assessment staging (FAST). , 1988, Psychopharmacology bulletin.
[7] G. Koch,et al. The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials , 1991 .
[8] B. Reisberg,et al. Functional Assessment Staging (FAST) in Alzheimer's Disease: Reliability, Validity, and Ordinality , 1992, International Psychogeriatrics.
[9] F. Orrego,et al. The chemical nature of the main central excitatory transmitter: A critical appraisal based upon release studies and synaptic vesicle localization , 1993, Neuroscience.
[10] M. Mega,et al. The Neuropsychiatric Inventory , 1994, Neurology.
[11] S. Lipton,et al. Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.
[12] F. Boller,et al. Severe impairment battery. A neuropsychological test for severely demented patients. , 1994, Archives of neurology.
[13] L. Margulis,et al. Swimming against the current. , 1997, The Sciences.
[14] L. Schneider,et al. The Severe Impairment Battery: Concurrent Validity and the Assessment of Longitudinal Change in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.
[15] M. Sano,et al. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.
[16] B. Reisberg,et al. Report of an International Psychogeriatric Association Special Meeting Work Group; Under the Cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association , 1997, International Psychogeriatrics.
[17] A R Dobbs,et al. Evaluating the Driving Competence of Dementia Patients , 1997, Alzheimer disease and associated disorders.
[18] J. Newcomer,et al. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. , 1998, Progress in brain research.
[19] B. Winblad,et al. Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.
[20] C. Shaw,et al. Glutamate Slows Axonal Transport of Neurofilaments in Transfected Neurons , 2000, The Journal of cell biology.
[21] M. Sano,et al. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease , 2000, Neurobiology of Aging.
[22] E. Shimizu,et al. NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. , 2000, Science.
[23] H. Feldman,et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.
[24] Anthony F. Jorm,et al. Definition and Epidemiology of Dementia: A Review , 2003 .